About Pfizer
Pfizer is a research-based global pharmaceutical company with its UK business headquarters in Surrey and global headquarters in New York. Pfizer discovers, develops, manufactures and markets leading prescription medicines for humans and animals, and many of the world's best-known consumer treatments.
Every month, over two million patients in the UK are prescribed a Pfizer medicine. It is estimated that on any given day, 40 million people around the world are treated with a Pfizer medicine.
Approximately 6,900 staff are employed by Pfizer in the UK and for every 1 person directly employed by Pfizer, it is estimated that a total of 4 jobs are supported by the company’s activities in the UK. Pfizer is the largest Research & Development (R&D) inward investor in the UK.
Pfizer’s site in Sandwich is the largest biomedical R&D facility in the UK, employing approximately 2,600 people. It is Pfizer’s European R&D headquarters and has produced some of the company’s most successful medicines, which have improved public health worldwide. In 2004, Pfizer invested more than £500 million in R&D in the UK. Sandwich also has a significant manufacturing facility.
Pfizer works closely with many diverse charities, local and national organisations and statutory agencies, undertaking a number of programmes, designed to improve the health and lives of local communities.
The Pfizer UK Foundation is one such vehicle through which Pfizer is working with local and national organisations, agencies and charities to reach out to assist initiatives that address health inequalities in the UK. Projects range from providing education about healthy lifestyles – obesity and smoking cessation – in socially deprived regions in the UK to, providing access to health care to minority and isolated communities.
Healthcare is undergoing significant change in the UK and across the world, and the impacts resulting from these changes are far-reaching. Pfizer believes that opening up dialogue, between a wide range of stakeholders – industry, government, regulators, think tanks, academics, professional, patient and consumer groups and the media is crucial to building sustainable and successful healthcare reform.
The New Statesman & Pfizer Policy Forum programme has been created to allow such debates to take place.
Pfizer's expertise in medicines and service delivery, and our knowledge and experience of operating in different healthcare systems around the world, enables us to make a significant contribution to these debates.
